AnaptysBio shares tumble after legal fight with GSK over cancer drug license reut.rs/4oVocmB
AnaptysBio shares tumble after legal fight with GSK over cancer drug license
Shares of AnaptysBio fell more than 5% on Friday after the U.S. drug developer and GSK's oncology unit, Tesaro, filed lawsuits against each other, with both claiming a breach of a partnership deal for a cancer drug.
reut.rs
November 21, 2025 at 9:50 PM
AnaptysBio shares tumble after legal fight with GSK over cancer drug license reut.rs/4oVocmB
AnaptysBio's Jemperli sales hit $644m in H1 2026, up 34% year-on-year. FDA decision on a rectal cancer indication expected February 2027.
AnaptysBio reports Jemperli royalties up 34% as FDA decision looms
AnaptysBio posted $644m in Jemperli global net sales for H1 2026 and expects an FDA ruling on a rectal cancer indication by February 2027.
biotech.disruptsmedia.com
September 22, 2026 at 6:55 AM
AnaptysBio's Jemperli sales hit $644m in H1 2026, up 34% year-on-year. FDA decision on a rectal cancer indication expected February 2027.
AnaptysBio $ANAB reported Q2 2026 Adj EPS of -$0.11, beating the -$0.46 estimate by 76.1%. Revenue of $27.5M beat the $21.7M estimate by 26.8%.
https://fundspec.ai/s/ANAB/earnings
Track what company insiders are actually buying and selling.
https://fundspec.ai/s/ANAB/earnings
Track what company insiders are actually buying and selling.
September 21, 2026 at 8:55 PM
AnaptysBio $ANAB reported Q2 2026 Adj EPS of -$0.11, beating the -$0.46 estimate by 76.1%. Revenue of $27.5M beat the $21.7M estimate by 26.8%.
https://fundspec.ai/s/ANAB/earnings
Track what company insiders are actually buying and selling.
https://fundspec.ai/s/ANAB/earnings
Track what company insiders are actually buying and selling.
Thoughts on this? >> AnaptysBio describes ‘JAK-like’ efficacy for PD-1 drug in
rheumatoid arthritis >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #productmarketing #pharma #healthcare
rheumatoid arthritis >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #productmarketing #pharma #healthcare
AnaptysBio describes ‘JAK-like’ efficacy for PD-1 drug in
rheumatoid arthritis
AnaptysBio is claiming success with longer follow-up data from a Phase 2b trial in rheumatoid arthritis as it looks for a partner to take its PD-1 drug into Phase 3. Back in February, the company ...
dlvr.it
June 4, 2025 at 3:56 PM
Thoughts on this? >> AnaptysBio describes ‘JAK-like’ efficacy for PD-1 drug in
rheumatoid arthritis >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #productmarketing #pharma #healthcare
rheumatoid arthritis >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #productmarketing #pharma #healthcare
For those thinking about how to target PD-1 to block autoimmunity...... this is transformative.
ir.anaptysbio.com/news-release...
ir.anaptysbio.com/news-release...
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months | AnaptysBio, Inc.
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placebo Achieved statistical significance on key secondary endp...
ir.anaptysbio.com
February 12, 2025 at 12:53 PM
For those thinking about how to target PD-1 to block autoimmunity...... this is transformative.
ir.anaptysbio.com/news-release...
ir.anaptysbio.com/news-release...
#$ANAB climbed in premarket after a $27.5M collaboration-revenue beat. Jemperli sales grew 26–34%; ignore the $5.11 EPS tax gain. notreload.xyz/xy/revenue-b...
Revenue Beat and Packed Calendar Lift ANAB After Earnings
AnaptysBio climbed in premarket after a $27.5M collaboration-revenue beat. Jemperli sales grew 26–34%; ignore the $5.11 EPS tax gain.
notreload.xyz
September 22, 2026 at 10:02 AM
#$ANAB climbed in premarket after a $27.5M collaboration-revenue beat. Jemperli sales grew 26–34%; ignore the $5.11 EPS tax gain. notreload.xyz/xy/revenue-b...
AnaptysBio stock hits 52-week low at $14.11 amid market challenges By Investing.com
In a challenging market environment, AnaptysBio Inc . (NASDAQ:) stock has touched a 52-week low, reaching a price level of $14.11 USD, a dramatic 66% decline from its 52-week high of $41.31. With a market…
In a challenging market environment, AnaptysBio Inc . (NASDAQ:) stock has touched a 52-week low, reaching a price level of $14.11 USD, a dramatic 66% decline from its 52-week high of $41.31. With a market…
AnaptysBio stock hits 52-week low at $14.11 amid market challenges By Investing.com
In a challenging market environment, AnaptysBio Inc . (NASDAQ:) stock has touched a 52-week low, reaching a price level of $14.11 USD, a dramatic 66% decline from its 52-week high of $41.31. With a market capitalization of $437 million and a beta of -0.13, the stock typically moves counter to broader market trends. According to InvestingPro analysis, the stock appears undervalued at current levels.
geniousgrow.online
December 23, 2024 at 2:51 PM
AnaptysBio stock hits 52-week low at $14.11 amid market challenges By Investing.com
In a challenging market environment, AnaptysBio Inc . (NASDAQ:) stock has touched a 52-week low, reaching a price level of $14.11 USD, a dramatic 66% decline from its 52-week high of $41.31. With a market…
In a challenging market environment, AnaptysBio Inc . (NASDAQ:) stock has touched a 52-week low, reaching a price level of $14.11 USD, a dramatic 66% decline from its 52-week high of $41.31. With a market…
Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a partnership deal for a cancer drug.
AnaptysBio shares tumble after legal fight with GSK over cancer drug license
Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a partnership deal for a cancer drug.
reut.rs
November 21, 2025 at 2:15 PM
Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a partnership deal for a cancer drug.
🚨 $ANABV
On September 21, 2026, AnaptysBio, Inc. issued a press release announcing its financial results for the three months and transitional fiscal year ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item ...
On September 21, 2026, AnaptysBio, Inc. issued a press release announcing its financial results for the three months and transitional fiscal year ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item ...
SEC Filing: ANABV
Click to view the official SEC document.
www.sec.gov
September 21, 2026 at 8:24 PM
🚨 $ANABV
On September 21, 2026, AnaptysBio, Inc. issued a press release announcing its financial results for the three months and transitional fiscal year ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item ...
On September 21, 2026, AnaptysBio, Inc. issued a press release announcing its financial results for the three months and transitional fiscal year ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item ...
Feed: "Endpoints News"
By: ENDPOINTS on Monday, November 10, 2025
By: ENDPOINTS on Monday, November 10, 2025
AnaptysBio reports Phase 2 fail in ulcerative colitis; Lyell's CAR-T licensing deal
Plus, news about Tenaya, AtaiBeckley, Galecto, Damora, A2 Biotherapeutics, AstraZeneca and Evommune
endpoints.news
November 10, 2025 at 6:25 PM
Feed: "Endpoints News"
By: ENDPOINTS on Monday, November 10, 2025
By: ENDPOINTS on Monday, November 10, 2025
Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)
Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB) - BeyondLink
Insider Monkey viewed a copy ofAlphyn Capital Management's second-quarter 2026 investor letter. The fund's Master Account returned 0.6% net in the quarter
beyondlink.live
September 16, 2026 at 5:02 AM
Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)
🚨 $ANABV
On August 11, 2026, AnaptysBio, Inc. held its 2026 Annual Meeting of Stockholders and the following proposals were adopted: 1. Election of two Class III directors, Hollings Renton and John P. Schmid, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockho...
On August 11, 2026, AnaptysBio, Inc. held its 2026 Annual Meeting of Stockholders and the following proposals were adopted: 1. Election of two Class III directors, Hollings Renton and John P. Schmid, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockho...
SEC Filing: ANABV
Click to view the official SEC document.
www.sec.gov
August 11, 2026 at 8:09 PM
🚨 $ANABV
On August 11, 2026, AnaptysBio, Inc. held its 2026 Annual Meeting of Stockholders and the following proposals were adopted: 1. Election of two Class III directors, Hollings Renton and John P. Schmid, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockho...
On August 11, 2026, AnaptysBio, Inc. held its 2026 Annual Meeting of Stockholders and the following proposals were adopted: 1. Election of two Class III directors, Hollings Renton and John P. Schmid, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockho...
What Makes AnaptysBio (ANAB) an Investment Bet?
Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment in Laughing…
Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment in Laughing…
What Makes AnaptysBio (ANAB) an Investment Bet?
Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment in Laughing Water Capital returning approximately 39.8% net of all fees and expenses, bringing the YTD return to approximately 33.6% net. [...]
news-area.com
July 15, 2026 at 2:58 AM
What Makes AnaptysBio (ANAB) an Investment Bet?
Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment in Laughing…
Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment in Laughing…
Itepekimab (Sanofi/Regeneron) and Tozorakimab (AstraZeneca) are anti-IL-33 antibodies in Phase III clinical development for COPD. Etokimab (AnaptysBio) is early in development. GSK had a license for CNTO 7160 but it targets IL-33 receptor and can’t figure out the status.
January 22, 2025 at 1:54 AM
Itepekimab (Sanofi/Regeneron) and Tozorakimab (AstraZeneca) are anti-IL-33 antibodies in Phase III clinical development for COPD. Etokimab (AnaptysBio) is early in development. GSK had a license for CNTO 7160 but it targets IL-33 receptor and can’t figure out the status.
AnaptysBio Director Schmid Sells $1.16M in ANAB Stock: Director Thomas Schmid sold $1.16M of ANAB stock on Apr 1–2, 2026 (Investing.com/SEC Form 4). Institutional investors should verify 10b5-1 coverage and watch for… 👈 Read full analysis #AnaptysBio #StockMarket #Investing #InsiderTrading #Biotech
AnaptysBio Director Schmid Sells $1.16M in ANAB Stock
Director Thomas Schmid sold $1.16M of ANAB stock on Apr 1–2, 2026 (Investing.com/SEC Form 4). Institutional investors should verify 10b5-1 coverage and watch for clustered insider activity.
dlvr.it
April 2, 2026 at 2:14 AM
AnaptysBio Director Schmid Sells $1.16M in ANAB Stock: Director Thomas Schmid sold $1.16M of ANAB stock on Apr 1–2, 2026 (Investing.com/SEC Form 4). Institutional investors should verify 10b5-1 coverage and watch for… 👈 Read full analysis #AnaptysBio #StockMarket #Investing #InsiderTrading #Biotech
Anaptysbio CEO Sells $1.1M in Shares: Anaptysbio CEO Faga sold $1.1M of ANAB stock on Mar 27, 2026 (Investing.com); institutional investors should verify SEC Form 4 and assess ownership impact. 👈 Read full analysis #Anaptysbio #CEO #StockMarket #Investing #Biotech
Anaptysbio CEO Sells $1.1M in Shares
Anaptysbio CEO Faga sold $1.1M of ANAB stock on Mar 27, 2026 (Investing.com); institutional investors should verify SEC Form 4 and assess ownership impact.
dlvr.it
March 28, 2026 at 12:41 AM
Anaptysbio CEO Sells $1.1M in Shares: Anaptysbio CEO Faga sold $1.1M of ANAB stock on Mar 27, 2026 (Investing.com); institutional investors should verify SEC Form 4 and assess ownership impact. 👈 Read full analysis #Anaptysbio #CEO #StockMarket #Investing #Biotech
2026-04-27 14:01:55 - GlaxoSmithKline (GSK): AnaptysBio seeks to revoke Tesaro’s license authorization for dostarlimab. Both GlaxoSmithKline and Tesaro firmly believe that the relevant accusations are completely unfounded, and we will continue to focus on advancing this claim in court.
April 27, 2026 at 6:10 AM
2026-04-27 14:01:55 - GlaxoSmithKline (GSK): AnaptysBio seeks to revoke Tesaro’s license authorization for dostarlimab. Both GlaxoSmithKline and Tesaro firmly believe that the relevant accusations are completely unfounded, and we will continue to focus on advancing this claim in court.